283. Acquired pure red cell aplasia Clinical trials / Disease details


Clinical trials : 18 Drugs : 42 - (DrugBank : 22) / Drug target genes : 19 - Drug target pathways : 98

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04423367
(ClinicalTrials.gov)
September 13, 20205/6/2020Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line TreatmentSafety and Efficacy of Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment: A Prospective Phase II TrialAcquired Pure Red Cell AplasiaDrug: bortezomib/dexamethasoneInstitute of Hematology & Blood Diseases HospitalNULLRecruiting18 Years70 YearsAll17Phase 2China